Berry & Company has been fortunate to work with many of today’s and tomorrow’s leaders in biotechnology, life sciences, healthcare, real estate, publishing, investment banking and other areas.

Over the past decade we have executed public relations programs to support many different areas of Genzyme, one of the world’s most successful biotechnology companies. Our programs have included media relations support for several new product launches as well as awareness and patient education campaigns related to knee cartilage repair, lysosomal storage disorders, kidney disease, hereditary angioedema and other therapeutic areas.

For the world’s largest pharmaceutical company, we developed a campaign to help more people get involved in patient support in America. For another division of Pfizer we developed an awareness campaign to help parents learn about healthy growth in children. The program is being rolled out in countries around the world. We also produce a quarterly newsletter profiling Pfizer’s action to promote health education.

We worked to promote Esperion’s research in HDL therapy. Our efforts helped the company to earn extensive international attention for a technique using HDL “good” cholesterol to treat atherosclerosis. We also coordinated media outreach when Esperion was acquired by Pfizer at the end of 2003.

Using leading treatment specialists from across the country, we developed a national awareness campaign to help more families learn about the serious and sometimes life-threatening symptoms of hereditary angioedema. The campaign includes national and local media outreach as well as office materials, presentations and Web site inserts.

For a world leader in research and treatment in reproductive medicine, we provide services including national and local media relations, media training, patient materials development, radio and print advertising and ongoing counsel. We also regularly identify opportunities for members of the medicalteam to speak before influential patient organizations and to provide perspectives on advances in reproductive medicine for national and local media.

A recently-founded biotechnology company focusing on cardiovascular disease and HDL therapy, Cerenis was preparing to announce its first round of private equity financing. We helped them to complete and launch a new website within only a few weeks and developed a media strategy that positioned the company as an emerging leader in a very competitive and high-profile research area targeting atherosclerosis.

For a leader in the development of innovative therapies for infectious disease,we created a new and more comprehensive web site and corporate information kit. We are conducting an ongoing national media relations campaign to highlight the company’s commercial opportunities targeting multiple diseases including PCP, malaria and African sleeping sickness.

We coordinated media relations surrounding both the U.S. and European marketing clearances for the company’s innovative synthetic bone repair material. We provide ongoing counsel and media support related to new product development, product launches, marketing, and clinical trial enrollment.